C12Y 101/01051
3 -beta-hydroxysteroid dehydrogenase
Official title: 3 (or 17)-Beta-hydroxysteroid dehydrogenase (1.1.1.51)
C12Y101/01051 (3 -beta-hydroxysteroid dehydrogenase) appears on 10 US grants and 19 published applications in this corpus.
Search patents in C12Y- Granted patents
- 10
- Published applications
- 19
- Assignees
- 12
- Inventors
- 56
- Latest grant
- 10 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 2 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 3 |
| 2019 | 1 | 0 |
| 2020 | 1 | 3 |
| 2021 | 2 | 1 |
| 2022 | 1 | 3 |
| 2023 | 3 | 3 |
| 2024 | 0 | 4 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Enabling cholesterol catabolism in mammalian cells lacking same10 Feb 2026US 12,545,918 B2University of South Alabama Foundation for Research and Commercialization
- HSD17B13 variants and uses thereof19 Dec 2023US 11,845,963 B2Regeneron Pharmaceuticals, Inc.
- HSD17B13 variants and uses thereof12 Sep 2023US 11,753,628 B2Regeneron Pharmaceuticals, Inc.
- Compostions and methods for enabling cholesterol catabolism in human cells28 Mar 2023US 11,612,619 B2National Institute of Health (NIH), U.S. Dept. Of Health and Human Services (DHHS), U.S. Government
- HSD17B13 variants and uses thereof1 Nov 2022US 11,485,958 B2Regeneron Pharmaceuticals, Inc.
- Microbiome microorganism and uses thereof11 Jul 2024US 2024/0226189 A1Biomica Ltd.
- Microbial consortium and uses thereof11 Jul 2024US 2024/0226195 A1Biomica Ltd.
- Sirna targeting 17beta-hydroxysteroid dehydrogenase type 13 and sirna conjugate11 Jul 2024US 2024/0229037 A1Tuojie Biotech (Shanghai) Co., Ltd.
- Hsd17b13 variants and uses thereof2 May 2024US 2024/0141305 A1Regeneron Pharmaceuticals, Inc.
- Specific substrates and products of hsd17b13 as markers of liver disease and biomarkers for liver disease treatment28 Dec 2023US 2023/0416802 A1Inipharm, Inc.
Most cited
By later US patents
- HSD17B13 variants and uses thereof10US 10,787,647 B2Regeneron Pharmaceuticals, Inc. · 2020
- Compostions and methods for enabling cholesterol catabolism in human cells2US 11,612,619 B2National Institute of Health (NIH), U.S. Dept. Of Health and Human Services (DHHS), U.S. Government · 2023
- HSD17B13 variants and uses thereof1US 11,485,958 B2Regeneron Pharmaceuticals, Inc. · 2022
- HSD17B13 variants and uses thereof1US 11,753,628 B2Regeneron Pharmaceuticals, Inc. · 2023
- HSD17B13 variants and uses thereof1US 11,845,963 B2Regeneron Pharmaceuticals, Inc. · 2023